Announcement • May 19
Cytogen, Inc. announced that it expects to receive KRW 5.2 billion in funding from BNK Securities Co.,Ltd., Hanyang Securities Co. Ltd. and other investors.
Cytogen, Inc. announced private placement to issue Zero Coupon Series 7 Bearer-type, unsecured private placement convertible bonds due May 26, 2031 for gross proceeds of KRW 5,200,000,000 on May 18, 2026. The transaction includes participation from NH Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 1) for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 2) for KRW 500,000,000, Korea Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 3) for KRW 500,000,000, KB Securities Co.,Ltd (in its capacity as the trustee of Fund 4) for KRW 500,000,000, Samsung Securities Co.,Ltd. (in its capacity as the trustee of Fund 5) for KRW 1,000,000,000, BNK Securities Co.,Ltd. for KRW 1,000,000,000, Hanyang Securities Co. Ltd. for KRW 500,000,000, Lee Hoon-cheol for KRW 200,000,000. The bonds are zero coupon with no yield to maturity and will mature on May 26, 2031. The bonds are 100% convertible into 955,004 shares at a conversion price of KRW 5,445 at a conversion period from May 26, 2027 to April 26, 2031. The bonds are restricted and have a lock up period of 1 year. The transaction is approved by board of directors of the company and is expected to close on May 26, 2026.